Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Cut to $540.00 by Analysts at Oppenheimer
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target decreased by Oppenheimer from $550.00 to $540.00 in a report published on Wednesday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the pharmaceutical company’s stock. A number of other research firms have also issued reports on VRTX. Raymond James reaffirmed a “market perform” […]
More Stories
Fiducient Advisors LLC Has $277,000 Position in Eli Lilly and Company (NYSE:LLY)
Fiducient Advisors LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 60.0% in...
Measured Wealth Private Client Group LLC Buys 574 Shares of Valero Energy Co. (NYSE:VLO)
Measured Wealth Private Client Group LLC raised its stake in shares of Valero Energy Co. (NYSE:VLO – Free Report) by...
iShares Core S&P 500 ETF (NYSEARCA:IVV) Shares Sold by Sunburst Financial Group LLC
Sunburst Financial Group LLC lowered its stake in shares of iShares Core S&P 500 ETF (NYSEARCA:IVV – Free Report) by...
Measured Wealth Private Client Group LLC Sells 120 Shares of Morgan Stanley (NYSE:MS)
Measured Wealth Private Client Group LLC lessened its holdings in Morgan Stanley (NYSE:MS – Free Report) by 3.1% during the...
B. Riley Financial Discloses Additional Pledged Shares by Chairman and Co-CEO Bryant R. Riley
B. Riley Financial, Inc. (NASDAQ: RILY) recently revealed in an SEC filing that Bryant R. Riley, Chairman and Co-CEO of...
Goldstone Financial Group LLC Makes New Investment in Colgate-Palmolive (NYSE:CL)
Goldstone Financial Group LLC acquired a new stake in Colgate-Palmolive (NYSE:CL – Free Report) during the third quarter, Holdings Channel.com...